Related Experiment Videos
Application of evidence-based medical therapy is associated with improved outcomes after percutaneous coronary
Wissam A Jaber1, Ryan J Lennon, Verghese Mathew
1Mayo Clinic, Rochester, Minnesota 55905, USA.
Insights
Prescribing multiple evidence-based cardiovascular medications after percutaneous coronary intervention (PCI) significantly reduces long-term death and myocardial infarction risk. This medication strategy improves patient outcomes following successful PCI procedures.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Medicine
Background:
- Standard-of-care medication use after percutaneous coronary intervention (PCI) and its impact on long-term outcomes remain understudied.
- Optimizing post-PCI pharmacotherapy is crucial for improving patient prognosis.
Purpose of the Study:
- To investigate if prescribing evidence-based medications at discharge after successful PCI predicts long-term clinical outcomes.
- To assess the association between medication adherence and major adverse cardiovascular events.
Main Methods:
- A retrospective cohort study analyzed 7,745 patients undergoing successful PCI between 1998 and 2004.
- A medication score (MEDS) was developed, assigning points for antiplatelet, lipid-lowering, beta-blocker, and ACE inhibitor use.
- Outcomes included long-term death, myocardial infarction, and revascularization.
Main Results:
- Patients receiving 3-4 medication classes (MEDS 3-4) had higher-risk profiles but experienced lower death rates compared to those with MEDS 0-1 (8.9% vs 13%).
- Adjusted analysis showed MEDS 3-4 was associated with significantly lower mortality or myocardial infarction (HRs 0.72 and 0.67).
- No significant association was found between MEDS and target vessel revascularization.
Conclusions:
- The use of multiple evidence-based cardiovascular medications (antiplatelet, lipid-lowering, beta-blockers, ACE inhibitors) post-PCI is linked to improved outcomes.
- Comprehensive medication regimens are associated with reduced long-term risk of death or myocardial infarction after successful PCI.
Objectives:
We sought to determine whether the prescription of evidence-based medications at discharge after successful percutaneous coronary intervention (PCI) can predict long-term clinical outcome.
Background:
The association of standard-of-care drug utilization and long-term mortality and morbidity after PCI is not well studied.
Methods:
We performed a retrospective cohort study of successful PCI procedures performed on 7,745 patients between March 1, 1998, and December 31, 2004. Discharge medications were analyzed, and a medication score (MEDS) was developed. A MEDS of 1 was assigned for each of the following medication classes: 1) antiplatelet, 2) lipid-lowering, 3) beta-blocker, and 4) angiotensin-converting enzyme (ACE) inhibitor. The outcomes measured were long-term death, myocardial infarction, and revascularization.
Results:
Patients with MEDS of 3 to 4 had higher-risk profiles based upon standard clinical and angiographic criteria. Despite this, at a median follow-up of 36 months, patients with a MEDS of 3 or 4 were at lower risk of death than those with a MEDS of 0 or 1 (8.9%, 7.5%, and 13% for MEDS of 4, 3, and 0 to 1, respectively; p = 0.014). After adjustment for covariates, a MEDS of 3 to 4 was associated with significantly lower mortality or myocardial infarction in follow-up than a MEDS of 0 to 1 (hazard ratios of 0.72 and 0.67 for MEDS of 3 and 4, respectively; p < 0.01). There was no association between MEDS and target vessel revascularization.
Conclusions:
After successful PCI, the use of multiple evidence-based classes of cardiovascular medications--antiplatelet, lipid-lowering, beta-blockers, and ACE inhibitors--is associated with improved outcome free of death or MI.
Related Concept Videos
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:27Coronary Artery Disease V: Interprofessional Care
01:17Pericarditis III: Medical Management
01:20Angina V: Nursing Management